Multifocal fixed drug eruption to azithromycin
DOI:
https://doi.org/10.66344/jpad.19.3.2009.540References
Shiohara T, Nickoloff BJ, Sagawa Y et al. Fixed drug eruption. Expression of epidermal keratinocyte intercellular adhesion molecule-1 (ICAM-1). Arch Dermatol 1989; 125: 1371-6.
Shiohara T, Mizukawa Y, Teraki Y. Pathophysiology of fixed drug eruption: the role of skin resident T cells. Curr Opin Allergy Clin Immunol 2002; 4: 317-23.
Shiohara T, Mizukawa Y. Fixed drug eruption: A disease mediated by self-inflicted responses of intraepidermal T cells. Eur J Dermatol 2007; 17: 201-8.
Sehgal VN, Srivastava G. Fixed drug eruption (FDE): changing scenario of incriminating drugs. Int J Dermatol 2006; 45: 897-908.
Ada S, Yilmaz S. Ciprofloxacin-induced generalized bullous fixed drug eruption. Indian J Dermatol Venereol Leprol 2008; 74: 511-2.
Barbaud A, Reichert-Penetrat S, Trechot P et al. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol 1998; 139: 49-58.
Ozkaya-Bayazit E. Topical provocation in fixed drug eruption due to metamizole and naproxen. Clin Exp Dermatol 2004; 29: 419-22.
Gahalaut P, Alexander E. Azithromycin in ACNE: A protagonist for fixed drug reaction? Indian J Dermatol 2008; 53:100-1
Downloads
Published
How to Cite
Issue
Section
License
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
